Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
levonorgestrel, efavirenz · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| levonorgestrel, efavirenz | EXPERIMENTAL | healthy HIV-negative women of reproductive age were given levonorgestrel, efavirenz |
| Name | Type | Description |
|---|---|---|
| levonorgestrel, efavirenz | DRUG | - |
Inclusion Criteria: * Healthy, HIV-1 seronegative women of child-bearing age. Exclusion Criteria: * Current use of hormonal contraception * Pregnancy/Breast Feeding * Post-menopausal status * Obesity * Hepatitis B or C * Psychiatric illness * Active Substance Abuse
Top 20 of 28 competitors
Levonorgestrel, efavirenz is a combination of a hormonal emergency contraceptive and an HIV medication, studied for use in HIV infections and contraception. It is a small molecule drug being developed by Bristol-Myers Squibb Company. The drug is currently in Phase 1 clinical development and is investigational, not yet approved.
The specific molecular targets of levonorgestrel, efavirenz are not disclosed in the available information. The drug combines levonorgestrel, a progestin hormone used for emergency contraception, and efavirenz, an antiretroviral medication used to treat HIV. Its clinical study focuses on drug interactions between these components in HIV-infected women.
Levonorgestrel, efavirenz is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY. The company is conducting clinical research on this combination therapy for HIV infections and contraception.
Levonorgestrel, efavirenz is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, involving 24 participants, but the drug remains in early-stage clinical testing.
Levonorgestrel, efavirenz has one completed clinical trial registered as NCT00482963, titled 'A Study of the Drug Interactions Between a Hormonal Emergency Contraception and an HIV Medication.' This Phase 1 study enrolled 24 female participants in the United States, including healthy volunteers, and examined pharmacokinetics in the context of HIV infections and contraception.
Levonorgestrel, efavirenz is a combination of two existing drugs: levonorgestrel, the active ingredient in emergency contraceptives like Plan B, and efavirenz, an antiretroviral sold under the brand name Sustiva. However, this specific combination product is a distinct investigational drug being studied by Bristol-Myers Squibb, not a marketed formulation.